Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Q J Nucl Med Mol Imaging ; 59(2): 152-60, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25719487

ABSTRACT

Glucagon-like peptide 1 (GLP-1) receptors expression has been found on many types of cancer cells. In case of benign insulinoma the density of those receptors is even higher than the density of somatostatin receptors. This article presents the results of clinical trials proving the utility of GLP-1 receptors imaging. Scintigraphy or positron emission tomography with the use of GLP-1 analogues labelled with appropriate radioisotopes (111In, 99mTc, 68Ga, 18F or 64Cu) seem to be superior compared with other available techniques in diagnosis of hardly detectable benign insulinoma. While surgery is the only effective therapy for insulinoma patients, therefore proper preoperative localization of the tumor allows sparing operation. Glucagon-like peptide 1 receptors might become also a target for imaging of other tumors such as gastrinoma, pheochromocytoma and medullary thyroid cancer (MTC), which also were shown to overexpress this type of receptors. However, studies with larger groups of patients are required to prove the clinical usefulness of this indication. Moreover GLP-1 receptor imaging seems to be a potential tool to evaluate pancreatic beta cell mass (BCM). It may be useful in the early diagnosis of beta cell loss in preclinical phases of diabetes. The panceratic beta cells imaging may influence the prophylaxis of diabetes and management of diabetic patients. Presented results of clinical trials prove that glucagon-like peptide 1 receptor imaging might become helpful diagnostic strategy particularly in case of patients with benign insulinoma tumors, but also patients with gastrinoma, pheochromocytoma, medullary thyroid cancer and diabetes.


Subject(s)
Biomarkers, Tumor/metabolism , Glucagon-Like Peptide 1/metabolism , Pancreatic Neoplasms/diagnostic imaging , Pancreatic Neoplasms/metabolism , Peptides/metabolism , Radionuclide Imaging/methods , Venoms/metabolism , Exenatide , Forecasting , Glucagon-Like Peptide 1/analogs & derivatives , Humans , Isotope Labeling/methods , Molecular Imaging/methods , Molecular Imaging/trends , Radionuclide Imaging/trends , Radiopharmaceuticals/chemical synthesis , Radiopharmaceuticals/pharmacokinetics
2.
Ann Nucl Med ; 28(7): 688-92, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24595462

ABSTRACT

OBJECTIVE: To examine yttrium-90 distribution 1 and 72 h following its injection into a knee joint in patients with rheumatoid arthritis (RA). METHODS: In 14 RA patients we injected yttrium-90 into the affected knee joint using lateral approach. To assess the radioisotope distribution in the joint, the superimposed sequential SPECT and CT imaging was performed 1 and 72 h after the injection. We analyzed the percentage of radioisotope distribution in three predefined compartments of the knee joint (lower, upper medial, upper lateral). RESULTS: After 1 and 72 h, the mean percentage distributions were, respectively, 7.14 and 23.07% in lower; 21.42 and 15.38% in upper medial, and 71.42 and 61.53% in upper lateral compartment. The percentage of isotope deposition did not change significantly with time in any of the compartments (all p > 0.26). The deposition of isotope, both at 1 and 72 h, was significantly greater in upper lateral compartment, where the injection was performed, than in all other compartments (all p < 0.05). CONCLUSIONS: Using the SPECT/CT hybrid method, we proved that the majority of isotope is located at the compartment adjacent to the injection. Two injections targeting different compartments might improve the clinical efficacy of the procedure.


Subject(s)
Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/surgery , Knee Joint/surgery , Synovectomy , Tomography, Emission-Computed, Single-Photon , Tomography, X-Ray Computed , Arthritis, Rheumatoid/diagnostic imaging , Female , Humans , Male , Middle Aged , Yttrium Radioisotopes/metabolism
3.
Neurol Neurochir Pol ; 47(5): 450-5, 2013.
Article in English | MEDLINE | ID: mdl-24166566

ABSTRACT

BACKGROUND AND PURPOSE: Hydrogen magnetic resonance spectroscopy (1HMRS) is nowadays one of the basic tools for noninvasive brain metabolism assessment. The study focuses on the important problem of the influence of hormone fluctuation during the menstrual cycle on brain metabolism, assessed by 1HMRS for clinical diagnostics. MATERIAL AND METHODS: In 11 healthy regularly menstruating women, 1HMRS was performed at the start (phase I), in the middle (phase II) and at the end (phase III) of the menstrual cycle. The relative concentration ratios of 12 brain metabolites in every woman in all cycle phases were examined, in 6 different volumes of interest (VOIs). Finally, statistically significant differences in relative metabolite ratios between the phases examined in given locations were sought. RESULTS: Statistically significant relations between menstrual cycle phases and relative ratios of 4 metabolites - Lac/Cr, NAA/Cr, Glx1/Cr and Glx2/Cr - in different brain locations were found. In all locations, mean NAA/Cr ratios were greater in phase I compared to the other phases. A similar relationship was found for Glx1/Cr ratio in one location (left occipital lobe). For Lac/Cr and Glx2/Cr ratios, a higher mean ratio value was obtained in phase II compared to phases I and III in the right occipital lobe and left basal ganglia, respectively. CONCLUSIONS: Menstrual cycle phase should be considered in planning a date and interpretation of 1HMRS examination, performed for the verification of a disease manifesting as brain metabolite disturbances in the 1HMRS spectrum.


Subject(s)
Brain/metabolism , Hydrogen/metabolism , Magnetic Resonance Spectroscopy/methods , Menstrual Cycle/physiology , Adult , Basal Ganglia/metabolism , Female , Humans , Pilot Projects , Reference Values , Women's Health , Young Adult
4.
Int J Endocrinol ; 2013: 384508, 2013.
Article in English | MEDLINE | ID: mdl-23606839

ABSTRACT

Introduction. Epidemiological studies on medullary thyroid cancer (MTC) have shown that neither a change in stage at diagnosis nor improvement in survival has occurred during the past 30 years. In patients with detectable serum calcitonin and no clinically apparent disease, a careful search for local recurrence, and nodal or distant metastases, should be performed. Conventional imaging modalities will not show any disease until basal serum calcitonin is at least 150 pg/mL. The objective of the study was to present the first experience with labelled glucagon-like peptide-1 (GLP-1) analogue [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4 in the visualisation of MTC in humans. Material and Method. Four patients aged 22-74 years (two with sporadic and two with MEN2 syndrome-related disseminated MTC) were enrolled in the study. In all patients, GLP-1 receptor imaging was performed. Results. High-quality images were obtained in all patients. All previously known MTC lesions have been confirmed in GLP-1 scintigraphy. Moreover, one additional liver lesion was detected in sporadic MTC male patient. Conclusions. GLP-1 receptor imaging with [Lys(40)(Ahx-HYNIC-(99m)Tc/EDDA)NH2]-exendin-4 is able to detect MTC lesions. GLP-1 scintigraphy can serve as a confirmatory test in MTC patients, in whom other imaging procedures are inconsistent.

SELECTION OF CITATIONS
SEARCH DETAIL
...